Changes in the Prevalence of Human Papillomavirus Following a National Bivalent Human Papillomavirus Vaccination Programme in Scotland: A 7-Year Cross-Sectional Study
This article, published in The Lancet Infectious Diseases, reports on a cross-sectional study that examined effectiveness of the bivalent human papillomavirus (HPV) vaccine against HPV types 16, 18, 31, 33, 45, and other high-risk types, after the introduction of routine vaccination in Scotland in 2008. According to the authors' findings, prevalence of HPV types 16 and 18 reduced substantially seven years after vaccination, giving a vaccine effectiveness of 89.1 percent against these types for those vaccinated at age 12 to 13 years. Cross-protective types (HPV types 31, 33, 45) also showed significant vaccine effectiveness. The authors suggest that these findings be considered in cost-effectiveness models informing vaccine choice and models to shape the future of cervical screening programmes. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Kavanagh K, Pollock KG, Cuschieri K, et al.
» Visit web page (English)
(Located at www.thelancet.com)
Citation: Kavanagh K, Pollock KG, Cuschieri K, et al. Changes in the Prevalence of Human Papillomavirus Following a National Bivalent Human Papillomavirus Vaccination Programme in Scotland: A 7-Year Cross-Sectional Study. The Lancet Infectious Diseases. 2017;Early Online Publication.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)
Regions: North America and Europe